Hutch News

Hutch News

Stories tagged 'Aude Chapuis'

Good News at Fred Hutch

Celebrating faculty and staff achievements

Dec. 14, 2017

Fred Hutchinson Cancer Research Center has announced awards totaling $1 million to nine of its scientists through the Evergreen Fund, a unique grant program that supports homegrown research projects deemed attractive to potential commercial partners. This is the second year of Evergreen Fund awards. This is the second year of Evergreen Fund awards. The Hutch’s Business Development & Strategy office created the program in 2016 in an effort to encourage scientists to pursue creative ideas with commercial appeal. The goal is to speed research from the bench to the bedside while generating income from patent rights and partnerships with the business sector.

View story >


Science without borders

At Fred Hutch and other U.S. research centers, a global village works to cure cancer and other diseases

Oct. 16, 2017 | By Mary Engel / Fred Hutch Research Center

Fred Hutch, like other major U.S. cancer research centers, attracts top scientists from around the world working to cure cancer, HIV and other diseases

View story >


Triple therapy for rare skin cancer shows promise in small, early-stage trial

Combo of T-cell therapy, newly FDA-approved drug and another immune booster kept cancer at bay for three of four patients with metastatic Merkel cell carcinoma

May 31, 2017 | By Rachel Tompa / Fred Hutch News Service

In a small, ongoing clinical trial testing a combination of three therapies, three of four patients with advanced Merkel cell carcinoma went into complete remission.

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

March 31, 2017

Dr. Philip Greenberg elected to serve on AACR board of directors; five researchers receive awards to explore immunotherapy single-cell RNA sequencing.

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

March 3, 2017

Dr. Nancy Davidson, former VP Joe Biden and other cancer leaders share insights about disease that touches so many; Novel ‘barcode’ tracking of T cells in immunotherapy patients identifies likely cancer killers; and Fred Hutch/UW graduate student Qing Feng among this year’s 13 Weintraub award winners.

View story >


Immunotherapy shows promise in preventing leukemia relapse

Group of 12 high-risk patients who received engineered T cells after bone marrow transplant still in remission after more than two years

Dec. 5, 2016 | By Susan Keown / Fred Hutch News Service

For patients with high-risk acute myeloid leukemia, relapse after bone marrow transplant signals a low chance of survival. But results from a small trial of genetically engineered immune cells show promise for keeping these patients out of danger: Of the 12 AML patients who received this experimental T-cell therapy after a transplant put their disease in remission, all are still in remission after a median follow-up of more than two years.

View story >



GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.